Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Healthy Volunteers, Enteric Hyperoxaluria

In brief

The first stage of this study is a prospective, adaptive, Phase 1, first-in-human, randomized, controlled study evaluating safety, tolerability, and pharmacodynamics of NOV-001 in adult healthy volunteers. The second stage of this study is a prospective, randomized, single-blinded, placebo-controlled study of safety, tolerability, and early efficacy in patients with enteric hyperoxaluria.

Key facts

Study ID
NCT04909723
Run by
Novome Biotechnologies Inc
People needed
153
Starts
2021-06-02
Expected to finish
2023-04-06
Last updated by the study team
2023-05-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.